Susanna Hallberg

Research

My research focuses on treatment-related immunological complications in
multiple sclerosis, especially hypogammaglobulinemia, late onset neutropenia,
and infection risks in rituximab and other highly efficient therapies

Article: LANCET NEUROLOGY. 2022;21(8):693-703
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Al Nimer F; Sundstrom P; Gunnarsson M; Johansson R; Mellergard J; Rosenstein I; Ayad A; Sjoblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J

Phd Student, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2025-2028

Research School for Clinicians in Epidemiology 2019-2021, Epidemiology, KEP, Karolinska Institutet, 2019
University Medical Degree, Karolinska Institutet, 2002